Biosimilar of the monoclonal antibody immunoglobulin G1κ daratumumab in treatment regimens for multiple myeloma patients
Objeсtive : To evaluate the direct medical costs of treating multiple myeloma (MM) patients with daratumumab and its Russian biosimilar using subcutaneous (SC) and intravenous (IV) administration routes, while considering the patients’ body weights. Material and methods. The targeted patient population...